- Home
- MPLN vs ABOS Comparison
MPLN vs ABOS Comparison
Compare MPLN & ABOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MPLN
- ABOS
- Stock Information
- Founded
- MPLN 1980
- ABOS 1996
- Country
- MPLN United States
- ABOS United States
- Employees
- MPLN N/A
- ABOS N/A
- Industry
- MPLN Business Services
- ABOS Biotechnology: Pharmaceutical Preparations
- Sector
- MPLN Consumer Discretionary
- ABOS Health Care
- Exchange
- MPLN Nasdaq
- ABOS Nasdaq
- Market Cap
- MPLN 188.6M
- ABOS 171.8M
- IPO Year
- MPLN N/A
- ABOS 2021
- Fundamental
- Price
- MPLN $8.27
- ABOS $2.53
- Analyst Decision
- MPLN Hold
- ABOS Strong Buy
- Analyst Count
- MPLN 2
- ABOS 4
- Target Price
- MPLN $25.00
- ABOS $9.00
- AVG Volume (30 Days)
- MPLN 58.4K
- ABOS 245.2K
- Earning Date
- MPLN 11-05-2024
- ABOS 11-12-2024
- Dividend Yield
- MPLN N/A
- ABOS N/A
- EPS Growth
- MPLN N/A
- ABOS N/A
- EPS
- MPLN N/A
- ABOS N/A
- Revenue
- MPLN $942,614,000.00
- ABOS N/A
- Revenue This Year
- MPLN N/A
- ABOS N/A
- Revenue Next Year
- MPLN $1.07
- ABOS N/A
- P/E Ratio
- MPLN N/A
- ABOS N/A
- Revenue Growth
- MPLN N/A
- ABOS N/A
- 52 Week Low
- MPLN $6.35
- ABOS $2.08
- 52 Week High
- MPLN $69.20
- ABOS $5.09
- Technical
- Relative Strength Index (RSI)
- MPLN 40.76
- ABOS 41.30
- Support Level
- MPLN $7.61
- ABOS $2.85
- Resistance Level
- MPLN $9.15
- ABOS $3.36
- Average True Range (ATR)
- MPLN 0.83
- ABOS 0.25
- MACD
- MPLN -0.14
- ABOS -0.04
- Stochastic Oscillator
- MPLN 22.84
- ABOS 1.19
About MPLN MultiPlan Corporation
MultiPlan Corp is a provider of data analytics and technology-enabled solutions designed to bring affordability, efficiency, and fairness to the U.S. healthcare industry. The company interprets clients' needs and customizes solutions that combine its payment integrity, network-based, and analytics-based services. The Company's focus is being a value-added provider of data analytics and technology-enabled end-to-end cost management, payment and revenue integrity solutions to the U.S. healthcare industry.
About ABOS Acumen Pharmaceuticals Inc.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.